2011 JMSA Holiday Reception

Posted in Pages

fotolia winter holiday xsPlease join us at the annual JMSA Holiday Reception:

Location: Columbus Citizens Foundation
                  8 East 69th Street,  Manhattan, NYC
Date: Friday December 2nd, 2011
Time: 7:00 - 9:00PM.

Space is limited, so please kindly RSVP by Friday, November 25th to Mr. Kano at This email address is being protected from spambots. You need JavaScript enabled to view it., with your name and names of guests, affiliations and titles. Please encourage friends who may be interested in JMSA’s activities and mission to join the reception.

Members (regular and post-graduate) and one guest are free, and additional guests will be just $30 per person. Please send checks to the JMSA address below by November 25th. If your membership has lapsed, but would like to attend, please mail membership dues to the JMSA office: 100 Park Avenue, Suite 1600, New York, NY, 10017

We look forward to seeing you at the reception.  Have a lovely holiday season!

Drug News

Posted in Pages

What is "Drug News?" 

"Drug News" is a new resource offered by the JMSA to assist the layperson in managing the constantly changing landscape of pharmacology. It will provide the public with up-to-date information about common medications, including indications, contraindications, drug interactions, side effects, drug recalls, and the appearance of new drugs on the market. The goal is to help empower the patient in his or her own health care.

Institue for Safe Medical Practices "Do Not Crush List"

The Institue for Safe Medical Practices has identifed a list of oral medications which should not be crushed in order to ensure efficacy and prevent adverse events.


Institute for Safe Medical Practice's High-Alert Medications List

The Institute for Safe Medical Practice has identified these medications as having a heightened risk of causing significant patient harm when they are used in error. 


Pending and Recent Drug Approvals

Trivaris: The FDA has approved this injectable eye steroid suspension to  treat retinal disease.

Ustekinumab: An FDA panel voted to recommend approval for this injectable drug used to treat severe-to-moderate psoriasis. The FDA will vote on the drug by late September.

More Articles ...